Mupadolimab, the new antibody, is generating considerable focus within the medical community due to its specific mechanism of action. This anti-CD73 compound selectively inhibits CD73, a plasma enzyme involved in https://opensocialfactory.com/story26155248/the-novel-drug-an-innovative-cd73-blocking-therapeutic-shows-potential